Role of full-length osteoprotegerin in tumor cell biology

Cellular and Molecular Life Sciences

Volumn 66, Issue 5, 2009, Pages 841-851

  Zauli, G ^a   Melloni, E ^a   Capitani, S ^a   Secchiero, P ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Angiogenesis; Apoptosis; Osteoclasts; Osteoprotegerin; TRAIL

Indexed keywords

AMINO ACID; DEATH RECEPTOR; HEPARIN; IMMUNOGLOBULIN G1; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; HYBRID PROTEIN; IMMUNOGLOBULIN G;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BLOOD LEVEL; BONE DEVELOPMENT; BONE METASTASIS; BREAST TUMOR; CANCER MODEL; CANCER PATIENT; CELL SURVIVAL; CLINICAL TRIAL; CYTOLOGY; DRUG ACTIVITY; DRUG INHIBITION; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OSTEOLYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; SEQUENCE HOMOLOGY; TUMOR CELL; GENETICS; METABOLISM; NEOPLASM; OSTEOCLAST; PHYSIOLOGY;

CELL SURVIVAL; ENDOTHELIAL CELLS; HUMANS; IMMUNOGLOBULIN G; NEOPLASMS; NEOVASCULARIZATION, PHYSIOLOGIC; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; RECOMBINANT FUSION PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 63049093672     PISSN: 1420682X     EISSN: 15691632     Source Type: Journal    
DOI: 10.1007/s00018-008-8536-x     Document Type: Review

References (113)

1. Simonet, W. S., Lacey, D. L., Dunstan, C., Kelly, M., Char M. S., Luthy, R., Nhuyen, H. Q., Wooden, S., Bennett, L., Boone, T., Shimamoto, G., DeRose, M., Elliot, R., Coloi bero, A., Tan, H. L., Trail, G., Sullivan, J., Davy, E., Bucay, N Renshaw-Gegg, L., Hughes, T. M., Hill, D., Pattison, V Campbell, P., Sander, S., Van, G., Tarpley, J., Derby, P., Le R. and Boyle, W. J. (1997) Osteoprotegerin: A novel secret protein involved in the regulation of bone density. Cell 8 309-319.
2. Yamaguchi, K., Kinosaki, M., Goto, M., Kobayashi, ] Tsuda, E., Morinaga, T. and Higashino, K. (1998) Charactj ization and structural domains of human osteoclastogene: inhibitory factor. J. Biol. Chem. 273, 5117 -5123.
3. Schneeweis, L. A., Willard, D. and Milla, M. E. (2005)Functional dissociation of osteoprotegerin and its interacts with receptor activator of NF-B ligand. J. Biol. Chem. 28 41155-41164.
4. Theoleyre, S., Wittrant, Y., Tat, S. K., Fortun, Y., Redini, and Heymann, D. (2004) The molecular triad OPG/RAN RANKL: Involvement in the orchestration of pathophysi logical bone remodeling. Cytokine Growth Factor Rev. 1 457-475.
5. Nybo, M. and Rasmussen, L. M. (2008) Osteoproteger released from the vascular wall by heparin mainly deriv from vascular smooth muscle cells. Atherosclerosis [Epi ahead of print].
6. Irie, A., Takami, M., Kubo, H., Sekino-Suzuki, N., Kasahar K. and Sanai, Y. (2007) Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity. Bone 41, 165-174.
7. Vitovski, S., Phillips, J. S., Sayers, J. and Croucher, P. I. (2008) Investigating the interaction between osteoprotegerin and RANKL or TRAIL: Evidence for a pivotal role for osteo- protegerin in regulating two distinct pathways. J. Cell Biol. 282, 31601-31609.
8. Zhang, J., Dai, J., Qi, Y., Lin, D. L., Smith, P., Strayhorn, C., Mizokami, A., Fu, Z., Westman, J. and Keller, E. T. (2001) Osteoprotegerin inhibits prostate cancer-induced osteoclas- togenesis and prevents prostate tumor growth in the bone. J. Clin. Invest. 107,1235-1244.
9. Aktkins, G. J., Bouralexis, S., Haynes, D. R., Graves, S. E., Geary, S. M., Evdokiou, A., Zanettino, A., Hay, S. and Findlay, D. M. (2001) Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. Bone 28, 370-377.
10. Morony, S., Capparelli, C., Sarosi, I., Lacey, D. L., Dunstan, C. R. and Kostenuik, P. J. (2001) Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res. 61, 4432-4436.
11. Croucher, P. I., Shipman, C. M., Lippitt, J., Perry, M., Hijzen, A., Brabbs, A. C., van Beek, E., Holen, I., Skerry, T. M., Dunstan, C. R., Russel, G. R. and van Camp, B. and Vanderkerken, K. (2001) Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 98, 3534-3540.
12. Yonou, H., Kanomata, N., Goya, M., Kamijo, T., Yokose, T., Hasebe, T., Nagai, K., Hatano, T., Ogawa, Y. and Ochiai, A. (2003) Osteoprotegerin/ osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe immunodeficiency mice. Cancer Res. 63, 2096-2102.
13. Vanderkerken K., De Leenheer, E., Shipman, C., Asosingh, K., Willems, A., van Camp, B. and Croucher, P. (2003) Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res. 63, 287-289.
14. Zheng Y., Zhou, H., Brennan, K., Blair, J. M., Modzelewski, J., Seibel, M. J. and Dunstan, C. R. (2007) Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti- tumor actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone 40, 471 -478.
15. Gori, F., Hofbauer, L. C., Dunstan, C. R., Spelsberg, T. C., Khosla, S. and Riggs, B. L. (2000) The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal osteoblast lineage cells is developmentally regulated. Endocrinology 141, 4768-4776.
16. Hofbauer, L. C., Dunstan, C. R., Spelsberg, T. C., Riggs, B. L. and Khosla, S. (1998) Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem. Biophys. Res. Commun. 250, 776-781.
17. Udagawa, N., Takahashi, N., Yasuda, H., Mizuno, A., Itoh, K., Ueno, Y., Shinki, T., Gillespie, M. T., Martin, T. J., Higashio, K. and Suda, T. (2000) Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 141, 3478-3484.
18. Viereck, V., Grundker, C., Blaschke, S., Niederkleine, B., Siggelkow, H., Frosch, K. H., Raddatz, D., Emons, G. and Hofbauer, L. C. (2003) Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. J. Clin. Endocrinol. Metab. 88, 4206-4213.
19. Li, Y., Toraldo, G., Li, A., Yang, X., Zhang, H., Qian, W. P. and Weitzmann, M. N. (2007) B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood 109, 3839-3848.
20. Collin-Osdoby, P., Rothe, L., Anderson, F., Nelson, M., Maloney, W. and Osdoby, P. (2001) Receptor activator of NF- κB and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J. Biol. Chem. 276, 20659-20672.
21. Olesen P., Ledet, T. and Rasmussen, L. M. (2005) Arterial osteoprotegerin: Increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-α. Diabetologia 48, 561-568.
22. Haynes, D. R., Barg, E., Crotti, T. N., Holding, C., Weedon, H., Atkins, G. J., Zannetino, A., Ahern, M. J., Coleman, M., Roberts-Thomson, P. J., Kraan, M., Tak, P. P. and Smith, M. D. (2003) Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. Rheumatology 42, 123-134.
23. Shalhoub, V., Faust, J., Boyle, W. J., Dunstan, C., Kelley, M. J., Kaufman, S., Scully, S., van Auken, M. and Lacey, D. L. (1999) Osteoprotegerin and osteoprotegerin ligand effects on osteo- clast formation from human peripheral blood mononuclear cell precursors. J. Cell Biochem. 72, 251 -261.
24. Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D. and Galibert, L. A. (1997) A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390,175-179.
25. Lacey, D. L., Timms, E., Tan, H. L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., Hsu, H., Sullivan, J., Hawkins, N., Davy, E., Capparelli, C., Eli, A., Qian, Y. X., Kaufman, S., Sarosi, I., Shalhoub, V., Senaldi, G., Guo, J., Delaney, J. and Boyle. W. J. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176.
26. Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H. L., Elliott, G., Kelley, M. J., Sarosi, I., Wang, L., Xia, X. Z., Elliott, R., Chiu, L., Black, T., Scully, S., Capparelli, C., Morony, S., Shimamoto, G., Bass, M. B. and Boyle, W. J. (1999) Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. USA 96, 3540-3545.
27. Dougall, W. C., Glaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, T., Daro, E., Smith, J., Tometsko, M. E., Maliszewski, C. R., Armstrong, A., Shen, V., Bain, S., Cosman, D., Anderson, D., Morrissey, P. J., Peschon, J. J. and Schuh, J. (1999) RANK is essential for osteoclast and lymph node development. Genes Dev. 13, 2412-2418.
28. Kong, Y. Y., Yoshida, H., Sarosi, I., Tan, H. L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., Khoo, W., Wakeham, A., Dunstan, C. R., Lacey, D. L., Mak, T. W., Boyle, W. J. and Penninger, J. M. (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315-323.
29. Wong, B. R., Josien, R. and Choi, Y. (1999) TRANCE is a TNF family member that regulates dendritic cell and osteo- clast function. J. Leukoc. Biol. 65, 715-724.
30. Cundy, T., Hegde, M., Naot, D., Chong, B., King, A., Wallace, R., Mulley, J., Love, D. R., Seidel, J., Fawkner, M., Banovic, T., Callon, K. E., Grey, A. B., Reid, I. R., Middleton-Hardie, C. A. and Cornish, J. (2002) A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum. Mol. Genet. 11, 2119-2127.
31. Whyte, M. P., Obrecht, S. E., Finnegan, P. M., Jones, J. L., Podgornik, M. N., McAlister, W. H. and Mumm, S. (2002) Osteoprotegerin deficiency and juvenile Paget's disease. N. Engl. J. Med. 347, 175-184.
32. Bucay, N., Sarosi, I., Dunstan, C., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., Boyle, W. J. and Simonet, W. S. (1998) Osteoprotegerin deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12, 1260-1268.
33. Min, H., Morony, S., Sarosi, I., Dunstan, C. R., Capparelli, C., Scully, S., Van, G., Kaufman, S., Kostenuik, P. J., Lacey, D. L., Boyle, W. J. and Simonet, W. S. (2000) Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J. Exp. Med. 192, 463-474.
34. Kearns, A. E., Khosla, S. and Kostenuik, P. (2008) RANKL and OPG regulation of bone remodeling in health and disease. Endocr. Rev. 29,155-192.
35. Zauli, G. and Secchiero, P. (2006) The role of the TRAIL/ TRAIL receptors system in hematopoiesis and endothelial cell biology. Cytokine Growth Factor Rev. 17, 245 - 257.
36. Tecchio, C., Huber, V., Scapini, P., Calzetti, F., Margotto, D., Todeschini, G., Pilla, L., Martinelli, G., Pizzolo, G., Rivoltini, L. and Cassatella, M. A. (2004) IFN alpha-stimulated neutrophils and monocytes release a soluble form of TNF- related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells. Blood 103, 3837 - 3844.
37. Ashkenazi, A., Holland, P. and Eckhardt, S. G. (2008) Ligand- based targeting of apoptosis in cancer: The potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J. Clin. Oncol. 26, 3621-3630.
38. Emery, J. G., McDonnell, P., Brigham Burke, M., Deen, K. C., Lyn, S., Silverman, C., Dul, E., Appelbaum, E. R., Eichman, C., Di Prinzio, R., Dodds, R. A., James, E. I., Rosenberg, M., Lee, J. C. and Young, P. R. (1998) Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273, 14363-14367.
39. Cretney, E., Takeda, K., Yagita, H., Glaccum, M., Peschon, J. J. and Smyth, M. J. (2002) Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand deficient mice. J. Immunol. 168, 1356-1361.
40. Sedger, L. M., Glaccum, M. B., Schuh, J. C., Kanaly, S. T., Williamson, E., Kayagaki, N., Yun, T., Smolak, P., Le, T., Goodwin, R. and Gliniak, B. (2002) Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. Eur. J. Immunol. 32, 2246-2254.
41. Zerafa, N., Westwood, J. A., Cretney, E., Mitchell, S., Waring, P., Iezzi, M. and Smyth, M. J. (2005) TRAIL deficiency accelerates hematological malignancies. J. Immunol. 175, 5586-5590.
42. Secchiero, P. and Zauli, G. (2008) TNF-related apoptosis- inducing ligand and the regulation of hematopoiesis. Curr. Opin. Hematol. 15, 42-48.
43. Yun, T. J., Chaudhary, P. M., Shu, G. L., Frazer, J. K., Ewings, M. K., Schwartz, S. M., Pascual, V., Hood, L. E. and Clark, E. A. (1998) OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J. Immunol. 161, 6113-6121.
44. Truneh, A., Sharma, S., Silverman, C., Khandekar, S., Reddy, M. P., Deen, K. C., McLaughlin, M. M., Srinivasula, S. M., Livi, G. P., Marshall, L. A., Alnemri, E. S., Williams, W. V. and Doyle, M. L. (2000) Temperature-sensitive differential affinity of TRAIL for its receptors. J. Biol. Chem. 275, 23319-23125.
45. Schneeweis, L. A., Willard, D. and Milla, M. E. (2006) Functional dissection of osteoprotegerin and its interaction with RANK-L. J. Biol. Chem. 280, 41155-41164.
46. Cheng, X., Kinosaki, M., Takami, M., Choi, Y., Zhang, H. and Murali, R. (2004) Disabling of receptor activator of nuclear factor-kB (RANK) receptor complex by novel osteoprote- gerin-like peptidomimetics restores bone loss in vivo. J. Biol. Chem. 279, 8269-8277.
47. Holen, I., Croucher, P. I., Hamdy, F. C. and Eaton, C. L. (2002) Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res. 62,1619-1623.
48. Shipman, C. M. and Croucher, P. I. (2003) Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res. 63, 912-916.
49. Neville-Webbe, H. L., Cross, N. A., Eaton, C. L., Nyambo, R., Evans, C. A. and Coleman, R. E. (2004) Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res. Treat. 86, 269-279.
50. Sandra, F., Hendarmin, L. and Nakamura, S. (2006) Osteo- protegerin (OPG) binds with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): Suppression of TRAIL- induced apoptosis in ameloblastomas. Oral Oncol. 42, 415-420.
51. Holen, I. and Shipman, C. M. (2006) Role of osteoprotegerin (OPG) in cancer. Clin. Sci. 110, 279-291.
52. Zauli, G., Rimondi, E., Nicolin, V., Melloni, E., Celeghini, C. and Secchiero, P. (2004) TNF related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF. Blood 104, 2044-2050.
53. Kip1 accumulation in pre-osteoclast precursors. J. Cell. Physiol. 214, 117-125.
54. Roux, S., Lambert-Comeau, P., Saint-Pierre, C., Lepine, M., Sawan, B. and Parent, J. L. (2005) Death receptors, Fas and TRAIL receptors, are involved in human osteoclast apoptosis. Biochem. Biophys. Res. Commun. 333, 42-50.
55. Chamoux, E., Houde, N., Leeriger, K. and Roux, S. (2008) Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway. J. Cell. Physiol. 216, 536-542.
56. Colucci, S., Brunetti, G., Cantatore, F. P., Oranger, A., Mori, G., Pignataro, P., Tamma, R., Grassi, F. R., Zallone, A. and Grano, M. (2007) The death receptor DR5 is involved in TRAIL-mediated human osteoclast apoptosis. Apoptosis 12, 1623-1632.
57. Chagraouia, H., Sabria, S., Caprona, C., Villevalb, J. L., Vainchenkera, W. and Wendlinga, F. (2003) Expression of osteoprotegerin mRNA and protein in murine megakaryo- cytes. Exp. Hematol. 31,1081-1088.
58. Bord, S., Frith, E., Ireland, D. C., Scott, M. A., Craig, J. I. O. and Compston, J. E. (2005) Synthesis of osteoprotegerin and RANKL by megakaryocytes is modulated by oestrogen. Br. J. Haematol. 126, 244-251.
59. Shahbazi, S., Lenting, P. J., Fribourg, C., Terraube, V., Denis, C. V. and Christophe, O. D. (2007) Characterization of the interaction between von Willebrand factor and osteoprote- gerin. J. Thromb. Haemost. 5, 1956-1962.
60. De Maria, R., Zeuner, A., Eramo, A., Domenichelli, C., Bonci, D., Grignani, F., Srinivasula, S. M., Alnemri, E. S., Testa, U. and Peschle, C. (1999) Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1. Nature 401, 489-493.
61. Di Pietro, R., Secchiero, P., Rana, R., Gibellini, D., Visani, G., Bermis, K., Zamai, L., Miscia, S. and Zauli, G. (2001) Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor-related apoptosis- inducing ligand (TRAIL)-mediated cytotoxicity by selective up-regulation of TRAIL-R1. Blood 97, 2596- 2603.
62. Secchiero, P., Gonelli, A., Mirandola, P., Melloni, E., Zamai, L., Celeghini, C., Milani, D. and Zauli, G. (2002) TNF-related apoptosis-inducing ligand (TRAIL) induces monocytic maturation of both leukemic and normal myeloid precursors via a caspase-dependent pathway. Blood 100, 2421-2429.
63. Secchiero, P, Melloni, E., Heikinheimo, M., Mannisto, S., Di Pietro, R. and Zauli, G. (2004) TRAIL regulates normal erythroid maturation through an ERK-dependent pathway. Blood 103, 517-522.
64. Kakagianni, T., Giannakoulas, N. C., Thanopoulou, E., Galani, A., Michalopoulou, S., Kouraklis-Symeonidis, A. and Zoumbos, N. C. (2006) A probable role for TRAIL-induced apoptosis in the pathogenesis of marrow failure.Implications from an in vitro model and from marrow of aplastic anemia patients. Leuk. Res. 30, 713-721.
65. Campioni, D., Secchiero, P., Corallini, F., Melloni, E., Capitani, S., Lanza, F. and Zauli, G. (2005) Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. Am. J. Pathol. 166, 557-563.
66. Pigullo, S., Ferretti, E., Lanciotti, M., Bruschi, M., Candiano, G., Svahn, J., Haneline, L., Dufour, C., Pistoia, V., Concione, A. (2007) Human Fanconi A cells are susceptible to TRAIL- induced apoptosis. Br. J. Haematol. 136, 315-318.
67. Malyankar, U., Scatena, M., Suchland, K., Yun, T., Clark, E. and Giachelli, C. (2000) Osteoprotegerin is an otv|33-induced, NF-kB-dependent survival factor for endothelial cells. J. Biol. Chem. 275, 20959-20962.
68. Pritzker, L., Scatena, M. and Giachelli, C. (2004) The role of osteoprotegerin and tumor necrosis factor-related apoptosis- inducing ligand in human microvascular endothelial cell survival. Mol. Biol. Cell 15, 2834-2841.
69. Stefanescu, R., Bassett, D., Modarresi, R., Santiago, F., Fakruddin, M. and Laurence, J. (2008) Synergistic interactions between interferon-gamma and TRAIL modulate c-FLIP in endothelial cells, mediating their lineage-specific sensitivity to thrombotic thrombocytopenic purpura plasma-associated apoptosis. Blood 112, 340-349.
70. Cross, S. S., Yang, Z., Brown, N. J., Balasubramanian, S. P., Evans, C. A., Woodward, J. K., Neville-Webbe, H. L., Lippitt, J. M., Reed, M. W., Coleman, R. E., and Holen, I. (2006) Osteoprotegerin (OPG)-a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis ? Int. J. Cancer 118,1901-1908.
71. Waterman EA, Cross NA, Lippitt JM, Cross SS, Rehman I, Holen I, Hamdy FC, and Eaton CL (2007) The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: Implications for association studies with human cancers. Int. J. Cancer 121, 1958-1966.
72. Kobayashi-Sakamoto, M., Isogai, E., Hirose, K, and Chiba, I. (2008) Role of alpha(v) integrin in osteoprotegerin-induced endothelial cell migration and proliferation. Microvasc. Res. 76, 139-144.
73. McGonigle, J. S., Tae, G., Stayton, P. S., Hoffman, A. S. and Scatena, M. (2008) Heparin-regulated delivery of osteopro- tegerin promotes vascularization of implanted hydrogels. J. Biomater. Sci. Polym. 19,1021-1034.
74. Mosheimer, B. A., Kaneider, N. C., Feistritzer, C., Djanani, A. M., Sturn, D. H., Patsch, J. R. and Wiedermann, C. J. (2005) Syndecan-1 is involved in OPG-induced chemotaxis in human peripheral blood monocytes. J. Clin. Endocrinol. Metab. 90, 2964-2971.
75. Chua, C. C., Rahimi, N., Forsten-Williams, K. and Nugent, M. A. (2004) Heparan sulfate proteoglycans function as receptors for fibroblast growth factor-2 activation of extracellular signal-regulated kinases 1 and 2. Circ. Res. 94, 316-323.
76. Collin-Osdoby, P., Rothe, L., Anderson, F., Nelson, M., Maloney, W. and Osdoby, P. (2001) Receptor activator of NF- κB ligand and osteoprotegerin expression by human micro- vascular endothelial cells, regulation by inflammatory cyto- kines, and role in human osteoclastogenesis. J. Biol. Chem. 276, 20659-20672.
77. Secchiero, P., Corallini, F., Pandolfi, A., Consoli, A., Candido, R., Fabris, B., Celeghini, C., Capitani, S. and Zauli, G. (2006) An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am. J. Pathol. 169, 2236-2244.
78. Ben-Tal Cohen, E., Hohensinner, P. J., Kaun, C., Maurer, G., Huber, K. and Wojta, J. (2007) Statins decrease TNF-alpha- induced osteoprotegerin production by endothelial cells and smooth muscle cells in vitro. Biochem. Pharmacol. 73, 77-83.
79. Zauli, G., Corallini, F., Bossi, F., Fischietti, F., Durigotto, P., Celeghini, C., Tedesco, F. and Secchiero, P. (2007) Osteopro- tegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood 110, 536-543.
80. Mangan, S. H., Campenhout, A. V., Rush, C. and Golledge, J. (2007) Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-alpha associated with induction of angiopoietin-2. Cardiovasc. Res. 76, 494-505.
81. Nybo, M. and Rasmussen, L. (2008) The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: A systematic literature review. Eur. J. Endocrinol. 159,603-608.
82. Brandstrom, H., Stiger, F., Lind, L., Kahan, T., Melhus, H. and Kindmark, A. (2002) A single nucleotide polymorphism in the promoter region of the human gene for osteoprotegerin is related to vascular morphology and function. Biochem. Biophys. Res. Commun. 293,13-17.
83. Zauli, G., Pandolfi, A., Gonelli, A., Di Pietro, R., Guarnirei, S., Ciabattoni, G., Rana, R., Vitale, M. and Secchiero, P. (2003) TNF-related apoptosis-inducing ligand (TRAIL) sequentially up-regulates nitric oxide and prostanoid production in primary human endothelial cells. Circ. Res. 92, 732-740.
84. Secchiero, P., Gonelli, A., Carnevale, E., Milani, D., Pandolfi, A., Zella, D. and Zauli, G. (2003) TRAIL promotes the survival and proliferation of primary human vascular endo- thelial cells by activating the Akt and ERK pathways. Circulation 107, 2250-2256.
85. Secchiero, P., Corallini, F., di Iasio, M. G., Gonelli, A., Barbarotto, E. and Zauli, G. (2005) TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release. Blood 105, 3413-3419.
86. Murdoch, C., Muthana, M., Coffelt, S. B. and Lewis, C. E.(2008) The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 8, 618-631.
87. Brown, J. M., Vessella, R. L., Kostenuik, P. J., Dunstan, C. R., Lange, P. H. and Corey, E. (2001) Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin. Cancer Res. 10, 2977-2983.
88. Lipton, A., Ali, S. M., Leitzel, K., Chinchilli, V., Witters, L., Engle, L., Holloway, D., Bekker, P. and Dunstan, C. R. (2003) Serum osteoprotegerin levels in healthy controls and cancer patients. Clin. Cancer Res. 8, 2306-2310.
89. Eaton, C. L., Wells, J. M., Holen, I., Croucher, P. I. and Hamdy, F. C. (2004) Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. Prostate 59, 304-310.
90. Jung, K., Lein, M., Stephan, C., Von Hosslin, K., Semjonow, A., Sinha, P., Loening, S. A. and Schnorr, D. (2004) Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: Diagnostic and prognostic implications. Int. J. Cancer 111, 783-791.
91. Mizutani, Y., Matsubara, H., Yamamoto, K., Nan Li, Y., Mikami, K., Okihara, K., Kawauchi, A., Bonavida, B. and Miki, T. (2004) Prognostic significance of serum osteoprote- gerin levels in patients with bladder carcinoma. Cancer 101, 1794-1802.
92. Valero, C., Olmos, J. M., Rivera, F., Hernández, J. L., Vega, M. E. and Macías, J. G. (2006) Osteoprotegerin and bone mass in squamous cell head and neck cancer patients. Calfic. Tissue Int. 78, 343-347.
93. De Toni, E. N., Thieme, S. E., Herbst, A., Behrens, A., Stieber, P., Jung, A., Blum, H., Göke, B. and Kolligs, F. T. (2008) OPG is regulated by beta-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer. Clin. Cancer Res. 14, 4713-4718.
94. Pettersen, I., Bakkelund, W., Smedsrød, B., Sveinbjørnsson, B. (2005) Osteoprotegerin is expressed in colon carcinoma cells. Anticancer Res. 25, 3809-3816.
95. Ito, R., Nakayama, H., Yoshida, K., Kuraoka, K., Motoshita, J., Oda, N., Oue, N. and Yasui, W. (2003) Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma. Virchows Arch. 443,146-151.
96. Toruner, M., Fernandez-Zapico, M., Sha, J. J., Pham, L., Urrutia, R. and Egan, L. J. (2006) Anti-anoikis effect of nuclear factor-κB through upregulated expression of osteo-protegerin, Bcl-2 and IAP-1. J. Biol. Chem. 281, 8686-8696.
97. Narita, N., Yuasa, T., Tsuchiya, N., Kumazawa, T., Narita, S., Inoue, T., Ma, Z., Saito, M., Horikawa, Y., Satoh, S., Ogawa, O. and Habuchi, T. (2008) A genetic polymorphism of the osteoprotegerin gene is associated with an increased risk of advanced prostate cancer. BMC Cancer 8, 224.
98. Chanda, D., Isayeva, T., Kumar, S., Siegal, G. P., Szafran, A. A., Zinn, K. R., Reddy, V. V. and Ponnazhagan, S. (2008) Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis. Mol. Ther. 16, 871-878.
99. Fisher, J. L., Thomas-Mudge, R. J., Elliott, J., Hards, D. K., Sims, N. A., Slavin, J., Martin, T. J. and Gillespie, M. T. (2006) Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Cancer Res. 66, 3620-3628.
100. Kapoor, P., Suva, L. J., Welch, D. R. and Donahue, H. (2008) Osteoprotegrin and the bone homing and colonization potential of breast cancer cells. J. Cell Biochem. 103, 30-41.
101. Weber, C. H. and Vincenz, C. (2001) The death domain superfamily: A tale of two interfaces? Trends Biochem. Sci. 26,475-481.
102. Eriksen, E. F., Eghbali-Fatourechi, G. Z. and Sundeep Khosla, S. (2007) Remodeling and vascular spaces in bone. J. Bone Miner. Res. 22, 1 -6.
103. Hauge, E. M., Qvesel, D., Eriksen, E. F., Mosekilde, L. and Melsen, F. (2001) Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblas- tic markers. J. Bone Miner. Res. 16, 1575-1582.
104. Schwarz, E. M. and Ritchlin, C. T. (2007) Clinical development of anti-RANKL therapy. Arthritis Res. Ther. 9 (Suppl1), S7.
105. Fu, M., Zhang, J., Lin, Y., Zhu, X., Willson, T. and Chen, Y. (2002) Activation of peroxisome proliferator-activated re- ceptor-g inhibits osteoprotegerin gene expression in human aortic smooth muscle cells. Biochem. Biophys. Res. Com-mun. 294, 597-501.
106. Secchiero, P., Corallini, F., Rimondi, E., Chiaruttini, C., di Iasio, M. G., Rustighi, A., Del Sal, G. and Zauli, G. (2008) Activation of the p53 pathway down-regulates the osteopro- tegerin (OPG) expression and release by vascular endothelial cells. Blood 111, 1287-1294.
107. Vassilev, L. T. (2007) MDM2 inhibitors for cancer therapy. Trends Mol. Med. 13, 23-31.
108. Stühmer, T., Chatterjee, M., Hildebrandt, M., Herrmann, P., Gollasch, H., Gerecke, C., Theurich, S., Cigliano, L., Manz, R. A., Daniel, P. T., Bommert, K., Vassilev, L. T. and Bargou, R. C. (2005) Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood 106, 3609-3617.
109. Secchiero, P., Barbarotto, E., Tiribelli, M., Zerbinati, C., di Iasio, M. G., Gonelli, A., Cavazzini, F., Campioni, D., Fanin, R., Cuneo, A. and Zauli, G. (2006) Functional integrity of the p53-mediated apoptotic pathway induced by the nongeno-toxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood 107, 4122-4129.
110. Saddler, C., Ouillette, P., Kujawski, L., Shangary, S., Talpaz, M., Kaminski, M., Erba, H., Shedden, K., Wang, S. and Malek, S. N. (2008) Comprehensive biomarker and genomic analysis identifies P53 status as the major determinant of response to MDM2 inhibitors in chronic lymphcytic leukemia. Blood 111, 1584-1593.
111. Secchiero, P., Zerbinati, C., Melloni, E., Milani, D., Campio- ni, D., Fadda, R., Tiribelli, M. and Zauli, G. (2007) The MDM- 2 antagonist Nutlin-3 promotes maturation of acute myeloid leukemic blasts. Neoplasia 9, 853 - 861.
112. Secchiero, P., Corallini, F., Gonelli, A., Dell'Eva, R., Vitale, M., Capitani, S., Albini, A. and Zauli, G. (2007). Antiangio- genic activity of the MDM2 antagonist nutlin-3. Circ. Res. 100, 61 -69.
113. Zauli, G., Rimondi, E., Corallini, F., Fadda, R., Capitani, S.and Secchiero, P. (2007) The MDM2 antagonist Nutlin-3 suppresses the proliferation and differentiation of human pre- osteoclasts via a p53-dependent pathway. J. Bone Miner. Res. 22,1621-1630.